串联高剂量流感疫苗可提高浆细胞疾病患者持久血清免疫
该随机双盲安慰剂对照试验纳入122例浆细胞疾病患者,比较串联高剂量Fluzone疫苗与标准接种。
要点
- 串联高剂量流感疫苗较标准接种显著提高浆细胞疾病患者血清保护率。
- 串联高剂量组流感季末血清保护率仍显著高于对照组。
- 该策略可能也适用于其他新发病原体疫苗。
核心结论
- 浆细胞疾病患者间隔30天接种两剂高剂量流感疫苗可产生更高且更持久的血清学免疫应答。
研究设计与样本
- 随机双盲安慰剂对照临床试验,纳入122例浆细胞疾病患者,47例接受标准接种,75例接受两剂高剂量Fluzone疫苗。
关键数值与推荐
- 标准接种为单剂年龄基础接种(<65岁标准剂量,≥65岁高剂量),对照组在第30天接受生理盐水安慰剂注射。
临床怎么用
- 对浆细胞疾病患者可考虑间隔30天接种两剂高剂量流感疫苗以提高血清保护率和持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination yields suboptimal protective immunity in these patients. Strategies to improve immunity to influenza in these patients are clearly needed. We performed a randomized, double-blind, placebo-controlled clinical trial comparing tandem Fluzone High-Dose influenza vaccination with standard-of-care influenza vaccination. Standard-of-care vaccination was single-dose age-based vaccination (standard dose, <65 years; high dose, ≥65 years), and patients in this arm received a saline placebo injection at 30 days. A total of 122 PCD patients were enrolled; 47 received single-dose standard-of-care vaccination, and 75 received 2 doses of Fluzone High-Dose vaccine. Rates of hemagglutinin inhibition (HAI) titer seroprotection against all 3 strains (H1N1, H3N2, and influenza B) were significantly higher for patients after tandem high-dose vaccination vs control (87.3% vs 63.2%; P = .003) and led to higher seroprotection at the end of flu season (60.0% vs 31.6%; P = .04). These data demonstrate that tandem high-dose influenza vaccination separated by 30 days leads to higher serologic HAI titer responses and more durable influenza-specific immunity in PCD patients. Similar vaccine strategies may also be essential to achieve protective immunity against other emerging pathogens such as novel coronavirus in these patients. This trial was registered at www.clinicaltrials.gov as #NCT02566265.
引用
- Branagan AR, Duffy E, Gan G, et al. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Adv. 2021. PMID: 33683337. doi:10.1182/bloodadvances.2020003880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。